510(k) Summary

SEP 1 3 2011

Submitter:

Captiva Spine

967 Alt A1A Suite 1 Jupiter, FL 33477 Phone: 877-772-5571 Fax: 866-318-322

Contact Person:

John Sanders

QualiReg Resources LLC 2361 NW 105th Ln Sunrise, FL 33322 Phone: 954-993-5581 Fax: 954-944-1910

Email: johnsanders@qualireg.com

Date Prepared:

September 8, 2011

Trade Name:

Captiva Spine CapLOX II Spinal System

Classification

Class II

Classification Name

Pedicle Screw Spinal System

Classification Number

21 CFR 888.3070

Product Code:

MNI, MNH

Predicate Device(s):

The subject device is substantially equivalent to the following devices:

K100956 Spondy Spinal Fixation System

K024096 Optima, Spinal System K950099 Synergy VLS System K100605 Spine Wave MIS System

Device Description:

The Captiva Spine CapLOX II Spinal System is a top-loading spinal fixation system consisting of polyaxial pedicle screws, cannulated polyaxial pedicle screws set screws, rods, and cross connectors assembled to create a rigid spinal construct. It is intended to provide stabilization during the development of fusion utilizing a bone graft as well as aid in the surgical

correction of various spinal deformities and pathologies in the

thoracolumbo-sacral iliac portion of the spine. The titanium alloy, single-use components are provided clean and non-sterile. Various sizes of the implants (screws and rods) are available to accommodate individual patient anatomy. The purpose of this submission is to add additional screws to the

pedicle screw system.

Indications for use/Intended Use

The CapLOX II Spinal System is a posterior, non-cervical pedicle fixation system intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the

treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar and sacral spine including degenerative spondylolisthesis with objective evidence of neurologic impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor, pseudoarthrosis and failed previous fusion.

In addition, when used as a pedicle screw fixation system, the CapLOX II Spinal System is intended for skeletally mature patients with severe spondylolisthesis (Grades 3 and 4) of the fifth lumbar-first sacral, L5-S1 vertebra, who are receiving fusion by autogenous bone graft only, who are having the device attached to the lumbar and sacral spine (levels may be from L3 to the sacrum/ilium), who are having the device removed after the attainment of a solid fusion.

Statement of Technological Comparison

Conclusion:

The subject spinal implant system is substantially equivalent to the above listed predicate devices in terms of materials, design, indications for use and operational principles.

Performance Data: Verification activities including FEA and engineering analysis indicates

Documentation provided demonstrates that the Captiva Spine CapLOX II

Spinal System is substantially equivalent to predicate devices.

subject device is substantially equivalent to predicates.







Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Captiva Spine, Inc. % QualiReg Resources, LLC Mr. John Sanders 2361 NW 105th Lane Sunrise, Florida 33322

SEP 1 3 2011

Re: K111115

Trade/Device Name: Captiva Spine CapLOX II Spinal System

Regulation Number: 21 CFR 888.3070

Regulation Name: Pedicle screw spinal system

Regulatory Class: Class II Product Code: MNI, MNH Dated: August 12, 2011 Received: August 15, 2011

Dear Mr. Sanders:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

__£ Mark N. Melkerson

Director

Division of Surgical, Orthopedic, and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

Device	Name: Cap	otiva Spine Capl	_OX II Spinal System
ndications for Use:			
mmobilization and stabilization reatment of the following ac- ncluding degenerative spond scoliosis, kyphosis, spinal tum	on of spinal seg ute and chronic ylolisthesis with or, pseudoarth	ments in skeletally ma instabilities or deforn n objective evidence o rosis and failed previo	
keletally mature patients wit vertebra, who are receiving fu	h severe spond Ision by autoge	lylolisthesis (Grades 3 mous bone graft only,	the CapLOX II Spinal System is intended for and 4) of the fifth lumbar-first sacral, L5-S1 who are having the device attached to the n), who are having the device removed after the
Prescription Use <u>X</u> (Part 21 CFR 801 Sub	part D)	AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
Conc	urrence of CI	DRH, Office of Dev	rice Evaluation (ODE)
	and Rest	Sign-Off) of Surgical, Orthopeo orative Devices umber KIIIII5	dic,